Consensus Alkem Laboratories Limited Bombay S.E.

Stocks

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - Bombay S.E. 18:02:32 22/09/2026 HKT			5-day change	1st Jan Change
5,337.15 ^INR	-0.24%		+4.87%	-3.05%

09-16	Alkem Laboratories Limited Launches Neuceno for the Treatment of Partial-Onset Seizures in Adult Patients	CI
09-15	Alkem Laboratories Limited Announces Appointment of Shubhadeep Sinha to Senior Management Position, Effective September 15, 2026	CI

c1ef85890e95d60e0afd728.NnCyTSq7s6mPCZDTXxyaouVvuxMVUfHBHQgYQsVaczI.UgngNE3q0svBaKaxalv17d0Elnh3IqOzVDl8CrcLPXVSRdwaB-z20P9tpA~342024d8c16a1c7c0c128b4878610e15

Analysts' recommendations: Alkem Laboratories Limited

05-29	Bob Capital Markets Downgrades Alkem Laboratories to Sell From Hold; Price Target is INR4,638	MT
05-29	Jefferies Adjusts Alkem Laboratories' Price Target to INR6,500 From INR6,550, Keeps at Buy	MT
02-16	Nomura Adjusts Alkem Laboratories' Price Target to INR6,890 From INR 6,860, Keeps at Buy	MT
02-16	IIFL Upgrades Alkem Laboratories to Buy from Add, Price Target is INR6,300	MT
11-17	Nomura Adjusts Alkem Laboratories' Price Target to INR6,860 From INR6,300, Keeps at Buy	MT
22/08/25	Nomura Adjusts Alkem Laboratories' Price Target to INR6,300 From INR5,430, Keeps at Buy	MT
13/08/25	Jefferies Upgrades Alkem Laboratories to Buy From Underperform, Adjusts Price Target to INR6,000 From INR4,460	MT
30/05/25	Jefferies Adjusts Alkem Laboratories' Price Target to INR4,460 From INR4,580, Keeps at Underperform	MT
27/02/25	Nomura Upgrades Alkem Laboratories to Buy From Neutral, Adjusts Price Target to INR5,430 From INR5,670	MT
10/02/25	Nomura Adjusts Alkem Laboratories' Price Target to INR5,670 From INR6,097, Keeps at Neutral	MT
10/02/25	Jefferies Adjusts Alkem Laboratories' Price Target to INR4,580 From INR5,080, Keeps at Underperform	MT
15/11/24	Nomura Adjusts Alkem Laboratories' Price Target to INR6,097 From INR6,061, Keeps at Neutral	MT
14/11/24	Jefferies Adjusts Alkem Laboratories' Price Target to INR4,950 From INR5,080, Keeps at Underperform	MT
14/08/24	Nomura Adjusts Alkem Laboratories' Price Target to INR6,061 From INR5,605, Keeps at Neutral	MT
12/08/24	Jefferies Adjusts Alkem Laboratories' Price Target to INR5,080 From INR4,200, Keeps at Underperform	MT
30/05/24	Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,200 From INR4,470, Keeps at Underperform	MT
12/02/24	Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform	MT
09/11/23	Nomura Upgrades Alkem Laboratories to Buy From Neutral, Adjusts Price Target to INR4,963 From INR3,632	MT
08/11/23	Jefferies Adjusts Alkem Laboratories’ Price Target to INR3,600 From INR3,550, Keeps at Underperform	MT
11/08/23	Jefferies Adjusts Alkem Laboratories' Price Target to INR3,550 From INR2,800, Keeps at Underperform	MT
23/05/23	Nomura Downgrades Alkem Laboratories to Neutral From Buy, Adjusts Price Target to INR3,632 From INR3,772	MT
14/02/23	Nomura Adjusts Alkem Laboratories' Price Target to INR3,772 From INR3,602, Keeps at Buy	MT
13/02/23	Jefferies Adjusts Alkem Laboratories' Price Target to INR2,800 From INR2,600, Keeps at Underperform	MT
10/01/23	Nomura Upgrades Alkem Laboratories to Buy From Neutral, Adjusts Price Target to INR3,602 From INR3,487	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+13.78%
	JOHNSON & JOHNSON					+3.13%
	ABBVIE INC.					+5.34%
	ROCHE HOLDING AG					+2.89%
	NOVARTIS AG					+7.94%
	ASTRAZENECA PLC					+25.8%
	AMGEN INC.					-1.39%
	NOVO NORDISK A/S					+18.79%
	GILEAD SCIENCES, INC.					+5.04%
	Average					+9.04%
	Weighted average by Cap.					+9.04%